



SOLUBILITY ENHANCEMENT OF RITONAVIR BY HOT MELT EXTRUSION 
Original Article 
 
SANJEEVANI DESAI*, JOHN DISOUZA, KIRAN MUSLE, HOSHMANI AVINASH 
Tatyasaheb Kore College of Pharmacy Warananagar, India 
Email: sanjeevanidesai@gmail.com     
 Received: 28 Oct 2015 Revised and Accepted: 03 Feb 2016 
ABSTRACT 
Objective: The enhancement of oral bioavailability of poorly water-soluble drugs remains one of the most challenging aspects of drug development. 
Therefore formulation approaches are being explored to enhance bioavailability of poorly water-soluble drugs. The aim of the present study was to 
prepare and characterize solid solution of water insoluble anti-HIV drug (Ritonavir).  
Methods: There are various techniques such as micronization, solubilization, salt formation, complexation with polymers, change in physical form, 
use of prodrug and drug derivatization, alteration in pH, the addition of surfactants, and others are used by which the dissolution and bioavailability 
of sparingly soluble drugs can be improved. Among the various approaches, the solid dispersion (SD) technique has often proved to be the most 
successful in improving the dissolution and bioavailability of the poorly soluble drug. Solid Solution were prepared by Hot Melt Extrusion technique 
at 1:1.5, 1:2 (Ritonavir: Soluplus) and 1:1.5:0.5 (Ritonavir: Soluplus: Leutrol F68/leutrol 127/TPGS) ratios respectively. Solid Solution was 
evaluated for Saturation solubility, dissolution rate, XRD, FTIR, DSC and SEM.  
Results: Among all prepared Solid solution systems, the systems which contain 1:2 ratios of Ritonavir and Soluplus, has shown 13 fold increases in 
solubility than pure Ritonavir. DSC, XRD and SEM results shown to change from crystalline to amorphous form for all ratios of Ritonavir.  
Conclusion: From the above results, it was concluded that the improved drug dissolution could be achieved by formulating Ritonavir as a solid 
solution with the polymers such as Soluplus. The low hygroscopicity and low glass transition temperature of Soluplus make it particularly suitable 
for hot melt extrusion. 
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INTRODUCTION 
Together with the permeability, the solubility behavior of a drug is a 
key determinant of its oral bioavailability. The poor solubility and 
low dissolution rate of drugs in the aqueous gastrointestinal fluids 
often cause insufficient bioavailability [1-4]. Ritonavir is a protease 
inhibitor with activity against Human Immunodeficiency Virus Type 
1 (HIV-1). Ritonavir is having poor solubility and low dissolution 
rate in the aqueous gastrointestinal fluids often cause insufficient 
bioavailability. Among various techniques like micronization, solid 
dispersion (SD), solubilization, salt formation, complexation, 
selected SD technique has often proved to be the most successful in 
improving the dissolution and bioavailability of poorly soluble drug 
because it is simple, economical and advantageous [5]. HME is the 
process of embedding drug in a polymeric carrier. Specifically, HME 
dosage forms are complex mixtures of API, functional excipients, and 
processing aids which are blended using industry-standard 
equipment [6]. The mixture is processed at elevated temperature 
and pressure, which disperses the drug in the matrix at a molecular 
level through the formation of a solid solution [7-9]. Hot-melt 
extrusion (Solid dispersion technology) can be used to improve the 
rate of dissolution of poorly soluble drugs [10]. Soluplus is a 
hydrophilic polymer have been used as a carrier for increasing the 
dissolution of a poorly water soluble Ritonavir. Soluplus is amphiphilic 
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer having 70 ⁰C as glass transition temperature and because of 
low glass transition temperature is suitable for hot melt extrusion 
process of Ritonavir. Leutrol F 68, Leutrol 127 and TPGS are used as 
solubilizer as well as a plasticizer. Thus, the aim of present 
investigation was to improve the dissolution rate of poorly water-
soluble Ritonavir by preparing its solid solution by hot melt extrusion. 
MATERIALS AND METHODS 
Materials 
Ritonavir was supplied by Lupin pharmaceutical ltd. Pune. Soluplus, 
Leutrol F 68, Leutrol 127 and TPGS were provided by BASF, Mumbai. 
All other chemicals used were of analytical grade. 
Method for preparation  
Prior to melt extrusion, Ritonavir was mixed with Soluplus, Leutrol F 
68, Leutrol 127, TPGS with different concentration ranges. This 
premixed powder was added into melting zone of 16 mm twin screw 
extruder. As components and concentration of batch changes the 
processing parameter (processing temperature, feed rate, torque, 
speed rate) changes. Then the molten material was extruded in 
compression zone and came through the cylindrical die with 2 mm 
diameter opening. The melt left the die plate as pale yellow, 
transparent, semisolid stands which were cooled through a conveyer 
belt with a pelletizer [11-13]. 
Characterization of solid dispersion 
Drug content 
Solid solution equivalent to 39 mg of Ritonavir were weighed 
accurately and dissolved in a suitable quantity of 0.1N HCl. The drug 
content was determined at 246 nm by UV-spectrophotometer 
(Shimadzu). 
Saturation solubility 
Saturation solubility of physical mixture and a solid solution 
prepared by hot melt method were determined by equilibrating 
excess physical mixture and solid solution in different media 
distilled water, 0.1 N HCl, phosphate buffer pH 6.8 and phosphate 
buffer pH 7.4. The suspension was stirred for 48 h by magnetic 
stirrer at 120 rpm at the temperature of 37.5±0.5 °C. The solution 
was centrifuged at 7000 rpm for 10 min supernatant was filtered 
through 0.45 membrane filter, appropriately diluted and analyzed 
for Ritonavir spectrophotometrically at 246 nm. 
In vitro drug release study  
The dissolution studies were performed using USP XXIV type II 
(paddle type) dissolution test apparatus (VEEGD, India). The 
samples equivalent to 100 mg Ritonavir were placed in dissolution 
vessel containing 900 ml 0.1N HCl maintained at 37±0.5 °C and 
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stirred at 50rpm. Samples were collected periodically and replaced 
with a fresh dissolution medium. After filtration through Whatman 
filter paper no.41, the concentration of Ritonavir was determined 
spectrophotometrically at 246 nm [14-16]. 
Fourier-transform Infrared spectroscopy (FTIR) 
Fourier-transform infrared (FTIR) spectra of Ritonavir solid solution 
extrudes obtained using IR spectrophotometer (Shimadzu, FTIR-
8400S, and Japan). The samples were scanned over the wave 
number range from 4000 to 400 cm–1
The XRPD patterns of solid solution samples of Ritonavir were 
recorded for 2θ between 4 ° to 50 ° at 0.1 ° intervals and a scanning 
rate of 6 s-
. 
Scanning electron microscopy (SEM)  
Microscopic observations of Ritonavir solid solution extrudes 
performed using a scanning electron microscope (SEM, JEOL JSM-6360 
A, Tokyo, Japan) at an acceleration voltage of 5kV [17]. Samples were 
sputtered (JEOL JFC-1600 Auto fine coater, Tokyo, Japan) with gold-
palladium and then observed at different magnifications. 
Differential scanning calorimetry (DSC) 
The DSC patterns were recorded by a heat flow method. Solid 
solution sample of Ritonavir (6-10 mg) was heated in crimped 
aluminum pans with a pierced lid at a scanning rate of 5 °C/min in 
an atmosphere of nitrogen gas purge (20 ml/min) using the range of 
0-300 °C. The DSC was calibrated for a baseline using empty pans, 
and for temperature and enthalpy using indium. 
X-ray powder diffraction (XRPD) 
1
RESULTS AND DISCUSSION 
 using a BRUKER D8 Advance (BRUKER AXS UK) 
diffractometer equipped with copper tube operating at 40 kV and 40 
mA. This analysis was performed at the University of Pune. 
Drug content 
The percentage drug content in various Ritonavir solid solution 
ranged formed 97.54±1.6 and 99.67±1.2. This indicated that 
Ritonavir was uniformly distributed in all of this prepared solid 
solution as shown in table 1. 
 
Table: 1 Drug content study 
Batch name Drug content (%) 
Ritonavir+Soluplus (1:1.5) 98.23 
Ritonavir+Soluplus (1:2) 99.67 
Ritonavir+Soluplus+Leutrol F 68 98.02 




Saturation solubility of pure Ritonavir was found to be 50 μg/ml, 
97.1 μg/ml, 11.51 μg/ml, 31.5 μg/ml in distilled water, 0.1 N HCl, 
phosphate buffer pH 6.8 and phosphate buffer pH 7.4 at room 
temperature as mention in table 2. A significant improvement in the 
saturation solubility was observed with a solid solution. 
  
Table 2: Saturation solubility of solid solution 
Batch name Solubility of solid solution in different media (µg/ml) 
Water 0.1 N HCl Phosphate buffer (pH 6.8) Phosphate buffer (pH 7.4) 
Ritonavir 50 97.1 11.5 31.5 
Ritonavir+Soluplus(1:1.5) 343.57 566.42 84.71 126.84 
Ritonavir+Soluplus(1:2) 362.14 602.85 147.8 255.26 
Ritonavir+Soluplus+Leutrol F 68 317.88 447.14 109.47 137.89 
Ritonavir+Soluplus+Leutrol 127 289.28 413.57 88.42 113.15 
Ritonavir+Soluplus+TPGS 332.85 499.28 80.92 123.17 
The increase in weight fraction of the hydrophilic polymer resulted in improved saturation solubility. The solid solution with Soluplus in 1:2 
Ritonavir-Soluplus ratio showed high saturation solubility which was significantly high as compared to pure drug and other solid solution. There 
was 7 to 13 fold increase in a solid solution of Ritonavir in distilled water, 0.1 N HCl, phosphate buffer pH 6.8 and phosphate buffer pH 7.4. The 
results showed that the carrier Soluplus was able to enhance the solubility of Ritonavir. 
 
In vitro drug release study 
Dissolution testing of 100 mg crystalline Ritonavir showed 27.36% 
release of drug in 2 h in 0.1 N HCl due to low solubility. In comparison, 
the solid solution of Solu plus and Ritonavir showed near about complete 
drug release and enhances 4 fold drug releases as compared with 
crystalline Ritonavir. The results are shown in the following fig. 1 (fig. 1). 
 
 
Fig. 1: In vitro drug release of solid solutions batches and Ritonavir 
It was cleared from the graph, as the concentration of Soluplus 
increases, there was a significant increase in the rate of release of 
Ritonavir solid solution. As Soluplus concentration enhance the rate 
of release ultimately Ritonavir dissolution.  
Fourier-transform infrared spectroscopy (FTIR) 
FTIR spectra revealed the formation of hydrogen bond which might 
be attributing enhanced dissolution of the drug. 
The FTIR spectra of crystalline Ritonavir show a characteristic peak at 
3358.60 cm-1 (N-H stretching). In comparison, spectra of the hot melt 
extrude solid solution show a significant change at 3358.60 cm-1, 
related to weakening or removal of the N-H stretching. The 
significant disappearance of N-H stretching in hot melt extruder 
solid solution of Ritonavir is strong evidence of H-bonding between 
the drug and polymer via the secondary amine group of Ritonavir. 
This may attribute to the possible interaction between the N-H 
group of Ritonavir and C=O group of Soluplus leading to the 
formation of the amide group. All other peaks of Ritonavir such as 
1738 cm-1
Scanning electron microscopy (SEM) 
are remain constant hence, the improved dissolution of 
Ritonavir further supported this fact. 
SEM photomicrograph of the solid solution indicated the smooth 
uniform surface due to the homogeneous molecular dispersion of the 
drug in the polymer. 
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Fig. 2: FTIR spectra of solid solution batches and Ritonavir 
  
 
Fig. 3: SEM photograph of, (a) pure Ritonavir, (b) Ritonavir-
Soluplus (1:1.5), (c) Ritonavir-Soluplus (1:2), (d) Ritonavir-
Soluplus-Leutrol F 68, (e) Ritonavir-Soluplus-Leutrol 127, (f) 
Ritonavir-Soluplus-TPGS 
 
SEM photograph of pure Ritonavir (a) appeared like needle-shaped, 
rectangular crystalline structure. Whereas from SEM photograph of 
the solid solution is shown in b, c, d, e, f respectively gives an idea 
about change in surface morphology and change in the crystalline 
structure of drug in amorphous form. This suggests that the drug 
was diffused in polymer and has been distributed uniformly in the 
carrier mass. 
Differential scanning calorimetry (DSC) 
Thermal analysis of Ritonavir by differential scanning calorimetry 
showed a characteristic sharp endothermic peak at 125.55˚C 
indicating the melting point of the drug. The DSC thermogram of the 
solid solution shows absences of characteristic melting endotherm 
of Ritonavir in all batches. As single glass transition of solid solution 
in case of Ritonavir-Soluplus (1:2) solid solution indicating the 
perfect miscibility of Ritonavir and Soluplus.  
 
Fig. 4: DSC of Ritonavir and solid solution batches 
 
As single glass transition temperature is characteristic of the 
thermoplastic system, the DSC thermogram shows complete 
amorphization of Ritonavir. 
X-ray powder diffraction (XRPD) 
XRPD was used to determine the crystallinity of the hot melt 
extrudes of a solid solution. The X-ray diffractograms of the solid 
solution were compared with those of crystalline drug.  
 
 
Fig. 5: XRD of, (f) pure Ritonavir, (e)Ritonavir-Soluplus (1:1.5), 
(d)Ritonavir-Soluplus(1:2), (c)Ritonavir-Soluplus-L F 68, 
(b)Ritonavir-Soluplus-L 127, (a)Ritonavir-Soluplus-TPGS 
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From above fig. it is observed that t semi rigid peaks were absent 
from the diffract grams of the hot melt extrude of a solid solution. 
Hence, the absence of peaks of crystallinity of pure Ritonavir 
indicated complete amorphization of Ritonavir in solid solution. 
Thus, amorphization of Ritonavir due to processing with Soluplus 
was the reason for the dissolution enhancement. 
CONCLUSION 
To enhance, the dissolution rate of Ritonavir with hydrophilic 
polymers such as Soluplus, Leutrol F 68, Leutrol 127 and TPGS, Solid 
solution were prepared by hot melt extrusion. The solid solution 
obtained by Hot melt method with Ritonavir: Soluplus ratio of 1:2 
showed 7-13 fold increase in saturation solubility of the drug in 
different media such as distilled water, 0.1 N HCl, phosphate buffer 
pH 6.8 and 7.4. In vitro drug release of a solid solution of Ritonavir-
Soluplus (1:2) in 0.1 N HCl showed highest drug release as compared 
to other batches. From the above results, it was concluded that the 
improved drug dissolution could be achieved by formulating 
Ritonavir as a solid solution with the polymers such as Soluplus. The 
low hygroscopicity and low glass transition temperature of Soluplus 
make it particularly suitable for hot melt extrusion, and the addition 
of a plasticizer is not required in case of Soluplus because of low 
glass transition temperature. 
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